Clinical Trial Update: Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial of adjunctive ganaxolone (GNX) for Tuberous Sclerosis Complex–related epilepsy in children and adults was terminated; results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberous Sclerosis Complex

Drugs mentioned

• ganaxolone (ganaxolone)

Snippet

Sponsor: Marinus Pharmaceuticals | Conditions: Tuberous Sclerosis Complex | Phase 3 | Status: TERMINATED | Results posted: 2025-10-01